Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decoding chemotherapy-induced peripheral neuropathy: ion channels, disease models, and future directions.

Frontiers in pharmacology·2026
Same author

Piezo2 mediates mechanical sensitivity and injury-induced hypersensitivity in MrgprD-expressing nociceptors.

Pain·2026
Same author

Small peptides derived from the autoinhibitory XY linker of phospholipase C-β isoforms inhibit enzyme activity and reduce inflammation.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Persistent in vitro nociceptor hyperexcitability and axonal retraction produced by repeated paclitaxel doses.

The FEBS journal·2026
Same author

Selective TRPV2 Antagonists Derived from the Natural Product Piperlongumine Inhibit Cancer Cell Migration and Metastasis.

ACS chemical biology·2026
Same author

Light-induced analgesia provides a drug-free optical method for pain relief via activation of TRAAK k<sup>+</sup> channels.

Nature communications·2026

Related Experiment Videos

TRPA1 modulators in preclinical development.

Félix Viana1, Antonio Ferrer-Montiel

  • 1Universidad Miguel Hernández-CSIC, Instituto de Neurociencias, Tenured Reserach Investigator CSIC, Avenida Santiago Ramón y Cajal, Alicante, Spain.

Expert Opinion on Therapeutic Patents
|November 27, 2009
PubMed
Summary
This summary is machine-generated.

Transient receptor potential ankyrin 1 (TRPA1) channels sense irritants and physical stimuli. Developing TRPA1 antagonists is crucial for treating pain conditions, with ongoing research aiming to improve their efficacy and safety.

Related Experiment Videos

Area of Science:

  • Neuroscience
  • Pharmacology
  • Sensory Biology

Background:

  • Transient receptor potential ankyrin 1 (TRPA1) is a key sensor for chemical irritants (foods, pollutants) and physical stimuli (cold, mechanical forces).
  • TRPA1 channels play a significant role in sensory biology and nociception.

Purpose of the Study:

  • To highlight the role of TRPA1 in pain pathophysiology, particularly cold and mechanical hyperalgesia in inflammatory and neuropathic states.
  • To discuss TRPA1 as a therapeutic target for drug development.

Main Methods:

  • Review of existing literature on TRPA1 receptor antagonists and agonists.
  • Analysis of medicinal chemistry efforts to optimize TRPA1 antagonist scaffolds for preclinical and clinical studies.

Main Results:

  • TRPA1 antagonists show promising in vivo activity against mechanical hypersensitivity and cold hyperalgesia.
  • Current TRPA1 antagonists require high therapeutic doses, posing challenges for drug development.
  • The number of reported TRPA1 antagonists is limited compared to agonists.

Conclusions:

  • TRPA1 is a significant therapeutic target for pain management.
  • Continued medicinal chemistry efforts are expected to yield improved TRPA1 antagonists with better therapeutic indexes.
  • TRPA1 agonists may also offer therapeutic potential, similar to capsaicin.